News
U.S. approves first-ever biannual shot to prevent HIV, but getting it might be hard
WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U.S. and abroad will get access to the powerful new option.
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...
Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from ...
Zacks Investment Research on MSN2d
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-TermIt doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
Investor's Business Daily on MSN3d
Gilead Sciences Wins Approval For Highly Effective HIV Prevention DrugGilead Sciences won Food and Drug Administration approval Wednesday for a highly effective drug to prevent HIV infection.
Gilead is now waiting for regulatory decisions on the twice-yearly PrEP in Europe and other markets, including South Africa ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback